The anti-obesity drug battle escalates! The CEO of Eli Lilly and Co reveals that the company's oral medication may be released early next year.

① Eli Lilly and Co's CEO David Ricks expects that its experimental oral weight-loss drug orforglipron will be approved as early as early 2026; ② The phase II trial data for orforglipron shows significant weight loss in participants, with clinical significance; ③ Although Eli Lilly and Co is once again trailing Novo-Nordisk A/S, its weight-loss injectable has completely surpassed semaglutide in head-to-head studies.

cls.cn40minutes ago

Eli Lilly CEO Expects New Weight Loss Pill to Be Approved Next Year

CNBC41minutes ago

Johnson & Johnson Makes $15 Billion Bet on Mental-health Drugs

MarketWatch53minutes ago

The Top and Bottom Contributors to S&P 500's Q4 EPS Growth

Seeking Alpha00:46

Express News | Eli Lilly and Co expects that its experimental weight-loss drug will be approved as early as early 2026.

BreakingsJan 13 23:42

Express News | Eli Lilly Is Projecting Approval of Its Experimental Weight-Loss Pill as Soon as Early 2026 - Bloomberg News

BreakingsJan 13 23:41